

Ref: FOI/GS/ID 9198

Please reply to:
FOI Administrator
Trust Management
Maidstone Hospital
Hermitage Lane
Maidstone, Kent
ME16 9QQ
Email: mtw-tr.foiadmin@nhs.net
www.mtw.nhs.uk

26 June 2024

Freedom of Information Act 2000

I am writing in response to your request for information made under the Freedom of Information Act 2000 in relation to renal cell carcinoma.

You asked: All questions are shown as received by the Trust.

Q1. How many patients have been treated in the past 3 months with the following agents for renal cell carcinoma (any stage):

- a. Avelumab + Axitinib*
- b. Axinitib*
- c. Cabozantinib*
- d. Everolimus*
- e. Lenvatinib + Everolimus*
- f. Lenvatinib + Pembrolizumab*
- g. Nivolumab monotherapy*
- h. Nivolumab + Cabozantinib*
- i. Nivolumab + Ipilimumab*
- j. Pazopanib*
- k. Pembrolizumab monotherapy*
- l. Pembrolizumab + Axitinib*
- m. Radiotherapy only*
- n. Sunitinib*
- o. Temsirolimus*
- p. Tivozanib*
- q. Other active systemic anti-cancer therapy*
- r. Palliative care only*

Q2. In the last 3 months, how many patients have undergone full or partial nephrectomy (any of the following OPCS codes M02.1, M02.2, M02.3, M02.4, M02.5, M03.1, M03.9, M04.2, M10.1 or M10.4)?

Q3. In the last 3 months, how many patients have been initiated on the following agents for treatment for Renal Cell Carcinoma?*

- a. Nivolumab (monotherapy)*

- b. Nivolumab + Ipilimumab
- c. Nivolumab + Cabozantinib
- d. Lenvatinib + Pembrolizumab
- e. Avelumab + Axitinib

**Patients are considered initiated if they have not been treated in the previous 6 months with any of the drugs that are part of the named regimen.*

Q4. Does your trust participate in any clinical trials for the treatment of renal cell carcinoma? If so please provide the name of each trial and number of patients that are taking part?

Trust response:

Q1	
a	3
b	5
c	7
d	3
e	0
f	12
g	6
h	0
i	2
j	9
k	3
l	0
m	12
n	1
o	0
p	0
q	0
r	6

Q2. None - Patients for planned Urology surgeries are referred to Medway Hospital

Q3	
a	1
b	0
c	0
d	4
e	0

Q4. We do not currently have any active trials for renal cell carcinoma.